» Articles » PMID: 18801070

Establishment and Characterization of in Vivo Human Tumor Models in the NOD/SCID/gamma(c)(null) Mouse

Overview
Journal Pathol Int
Specialty Pathology
Date 2008 Sep 20
PMID 18801070
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Immunodeficient mice are widely used for xenografts of human cells and tissue. The purpose of the present study was to investigate the characteristics of xenograft human tumor models using engraftment of various non-hematopoietic tumors in the NOD/SCID/gamma(c) (null) mouse. For tumor models, human solid tumor tissues were serially passaged three or more times to establish tissue lines. A total of 326 fresh tumor specimens, mainly gastrointestinal and female genital tissue, were engrafted with 54 established tissue lines. The types of tissue lines varied and included tumor tissue of both epithelial and mesenchymal origin. In some cases the original surgical specimen was replaced with large mononuclear cells. In the established tumor tissue lines, differentiation and tumor structure were similar to that of the original surgical specimen. The interstitium of the xenograft tissue in the tissue lines was relatively well preserved although slightly decreased and replaced by host tissue. These results indicate that human solid tumors can be successfully engrafted into the NOD/SCID/gamma(c) (null) mouse and that tissue lines with the characteristics of the original tumors can be established. Investigators in the field of tumor research will benefit from the availability of tissue lines that allow the establishment of more relevant in vivo human tissue models.

Citing Articles

Delta-6 desaturase FADS2 is a tumor-promoting factor in cholangiocarcinoma.

Hasegawa K, Fujimori H, Nakatani K, Takahashi M, Izumi Y, Bamba T Cancer Sci. 2024; 115(10):3346-3357.

PMID: 39113435 PMC: 11447924. DOI: 10.1111/cas.16306.


FAXC interacts with ANXA2 and SRC in mitochondria and promotes tumorigenesis in cholangiocarcinoma.

Fujimori H, Shima-Nakamura M, Kanno S, Shibuya-Takahashi R, Mochizuki M, Mizuma M Cancer Sci. 2024; 115(6):1896-1909.

PMID: 38480477 PMC: 11145136. DOI: 10.1111/cas.16140.


Patient-derived tumor models: a suitable tool for preclinical studies on esophageal cancer.

Liang F, Xu H, Cheng H, Zhao Y, Zhang J Cancer Gene Ther. 2023; 30(11):1443-1455.

PMID: 37537209 DOI: 10.1038/s41417-023-00652-9.


A novel VEGFR inhibitor ZLF-095 with potent antitumor activity and low toxicity.

Li X, Wang J, Wang Q, Luo T, Song X, Wan G Heliyon. 2023; 9(5):e15152.

PMID: 37251840 PMC: 10209341. DOI: 10.1016/j.heliyon.2023.e15152.


Circulating miRNAs in Breast Cancer Diagnosis and Prognosis.

Cardinali B, Tasso R, Piccioli P, Ciferri M, Quarto R, Del Mastro L Cancers (Basel). 2022; 14(9).

PMID: 35565446 PMC: 9101355. DOI: 10.3390/cancers14092317.